Consensus EPS · Q2 2026
-$0.10
Consensus revenue · Q2 2026
$21.4K
Analysts
7
Expected report
Aug 12, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 7 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $11.9K | $21.4K | $31K |
| EPS | -$0.12 | -$0.10 | -$0.10 |
| EBITDA | -$21.1K | -$14.6K | -$8.1K |
| EBIT | -$21.1K | -$14.6K | -$8.1K |
| Net income | -$10.2M | -$8.5M | -$7.6M |
- Revenue$21.4K
- EPS-$0.10
- EBITDA-$14.6K
- EBIT-$14.6K
- Net income-$8.5M
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
Revision trends appear once we have collected at least two daily snapshots for this period.
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for Ovid Therapeutics (OVID) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 0 analysts.
- Low
- $4.00
- Consensus
- $5.50
- Median
- $5.50
- High
- $7.00
- Current
- $2.22
- Upside
- +147.7%
Upside calculated vs most recent trading price of $2.22.
Consensus across all covering analysts. See the ranking ›
Analyst ratings
Consensus: Buy — based on 14 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 15, 2026 | Wedbush | maintain | Outperform | Outperform |
| Apr 9, 2026 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 26, 2026 | BTIG | maintain | Buy | Buy |
| Mar 20, 2026 | Wedbush | maintain | Outperform | Outperform |
| Dec 22, 2025 | HC Wainwright & Co. | maintain | Buy | Buy |
| Nov 24, 2025 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 27, 2025 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 24, 2025 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 24, 2025 | BTIG | maintain | Buy | Buy |
| Mar 12, 2025 | Wedbush | maintain | Outperform | Outperform |
- Apr 15, 2026WedbushOutperform
- Apr 9, 2026HC Wainwright & Co.Buy
- Mar 26, 2026BTIGBuy
- Mar 20, 2026WedbushOutperform
- Dec 22, 2025HC Wainwright & Co.Buy
- Nov 24, 2025HC Wainwright & Co.Buy
- May 27, 2025HC Wainwright & Co.Buy
- Mar 24, 2025HC Wainwright & Co.Buy
- Mar 24, 2025BTIGBuy
- Mar 12, 2025WedbushOutperform
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.